Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
low molecular weight heparin |
| gptkbp:approvedBy |
gptkb:FDA
1994 |
| gptkbp:ATCCode |
B01AB04
|
| gptkbp:brand |
gptkb:Fragmin
|
| gptkbp:CASNumber |
9041-08-1
|
| gptkbp:chemicalFormula |
C26H40N2O36S5
|
| gptkbp:contraindication |
history of heparin-induced thrombocytopenia
active major bleeding |
| gptkbp:discoveredBy |
gptkb:Pharmacia
|
| gptkbp:eliminationHalfLife |
2-4 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
dalteparin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits factor Xa and IIa (thrombin)
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
bleeding
thrombocytopenia injection site reactions |
| gptkbp:usedFor |
treatment of deep vein thrombosis
treatment of pulmonary embolism prevention of deep vein thrombosis prevention of pulmonary embolism prevention of clotting in hemodialysis |
| gptkbp:bfsParent |
gptkb:heparin
|
| gptkbp:bfsLayer |
6
|